Get all your news in one place.

100's of premium titles.
One app.

Start reading

Get all your news in one place.

100's of premium titles. One news app.

Start reading

INSANE: Curevac | Vintage Vibes

FTSE 100 edges down despite hopes of end to Russia-Ukraine war

Evening Standard · Aug 8, 2025

GSK to be paid up to £370 million after patent row settles in US

CureVac – a German pharmaceutical company – settled a long-running patent dispute with rival BioNTech and Pfizer in the US on Thursday.

Evening Standard · Aug 8, 2025

2 Small-Cap Stocks Set to Shine in a Bull Market

Small-cap growth-orientated stocks like HTCR and CVAC often outperform during bullish markets due to their sensitivity to improving economic conditions.

MarketBeat · Dec 16, 2024

From analysis to the latest developments in health,
read the most diverse news in one place.

US service sector shrinks for first time since May 2020; UK private sector growth slows in ‘pre-election seize up’ – as it happened

Eurozone private sector also loses momentum

The Guardian - UK · Jul 3, 2024

What are these 'cancer vaccines' I'm hearing about? And what similarities do they share with COVID vaccines?

Barely a month goes by without headlines announcing yet another advancement in cancer vaccines.

The Conversation · Mar 6, 2023

What are these ‘cancer vaccines’ making news? Are there similarities with COVID vaccines?

Using the same mRNA technology as COVID vaccines, cancer vaccines are an emerging personalised treatment for cancer.

The New Daily · Mar 6, 2023

‘This will happen before 2030’: how the science behind Covid vaccines might help to fight cancer

The success of mRNA-based drugs in combating coronavirus is inspiring scientists to create similar vaccines for melanoma and other tumours

The Guardian - UK · Jan 22, 2023

Read news from The Economist, FT, and more,
with one subscription

Warning Shots: CureVac Sues BioNTech Over COVID Vax Patents

Pharma giants CureVac are suing Pfizer’s vaccine partner BioNTech over the development of the vaccine credited with saving the world from COVID19.

Zenger · Jul 8, 2022

How To Attend CureVac Q4 2021 Earnings Conference Call

CureVac (NASDAQ:CVAC) will host a conference call at 09:00 AM ET on April 28, 2022, to discuss Q4 2021 earnings results. How to Attend CureVac (CVAC) Conference Call Follow this link to access the live webcast.

Benzinga · Apr 25, 2022

Germany Inks COVID-19 Vaccine Deal With CureVac, GSK Until 2029

Germany has signed a contract with CureVac BV (NASDAQ:CVAC) and its partner GlaxoSmithKline plc (NYSE:GSK) for domestically produced mRNA vaccines to bolster supplies for pandemic preparedness. The five-year contract allows for the production of up to 80 million doses at short notice until 2029, CureVac said, adding that those doses could be for the remainder of…

Benzinga · Apr 11, 2022

CureVac - GSK Start Dosing In Next-Gen COVID-19 Vaccine Candidate Trial

CureVac N.V. (NASDAQ:CVAC) dosed the first participant in a Phase 1 study of COVID-19 second-generation mRNA vaccine candidate, CV2CoV, developed with GlaxoSmithKline plc (NYSE:GSK). The clinical trial is expected to provide valuable data to evaluate further the performance of CureVac’s second-generation mRNA backbone, which has the potential to be applied broadly in future vaccines against…

Benzinga · Mar 30, 2022

BofA Downgrades CureVac On Limited 2022 Prospects

There is limited upside from CureVac BV’s (NASDAQ: CVAC) COVID-19 vaccine and there are few catalysts from the rest of the company’s pipeline in 2022, according to BofA Securities.

Benzinga · Jan 21, 2022

Coverage From

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Flutter Entertainment

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.